SpringWorks Therapeutics Reports First Quarter 2024
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the…
SpringWorks Therapeutics Reports First Quarter 2024
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the…
SpringWorks Therapeutics Announces European Medicines
STAMFORD, Conn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq:…